Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma.


Journal

Journal of gynecologic oncology
ISSN: 2005-0399
Titre abrégé: J Gynecol Oncol
Pays: Korea (South)
ID NLM: 101483150

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 26 11 2019
revised: 17 04 2020
accepted: 18 04 2020
entrez: 19 8 2020
pubmed: 19 8 2020
medline: 2 9 2021
Statut: ppublish

Résumé

Uterine serous carcinoma (USC) is a rare highly aggressive disease. In the present study, we aimed to investigate the survival implication of the systematic lymphadenectomy in patients who underwent surgery for apparent early-stage USC. Consecutive patients with apparent early-stage USC surgically treated at six Italian referral cancer centers were analyzed. A comparison was made between patients who underwent retroperitoneal staging including at least pelvic lymphadenectomy "LND" vs. those who underwent hysterectomy alone "NO-LND". Baseline, surgical and oncological outcomes were analyzed. Kaplan- Meier curves were calculated for disease-free survival (DFS) and disease-specific survival (DSS). Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). One hundred forty patients were analyzed, 106 LND and 34 NO-LND. NO-LND group (compared to LND group) included older patients (median age, 73 vs.67 years) and with higher comorbidities (median Charlson Comorbidity Index, 6 vs. 5) (p<0.001). No differences in terms of recurrence rate (LND vs. NO-LND, 33.1% vs. 41.4%; p=0.240) were observed. At Cox regression analysis lymphadenectomy did not significantly influence DFS (HR=0.59; 95% confidence interval [CI]=0.32-1.08; p=0.09), and DSS (HR=0.14; 95% CI=0.02-1.21; multivariable analysis p=0.07). Positive node was independently associated with worse DFS (HR=6.22; 95% CI=3.08-12.60; p<0.001) and DSS (HR=5.51; 95% CI=2.31-13.10; p<0.001), while adjuvant chemotherapy was associated with improved DFS (HR=0.38; 95% CI=0.17-0.86; p=0.02) and age was independently associated with worse DSS (HR=1.07; 95% CI=1.02-1.13; p<0.001). Although lymphadenectomy did not show survival benefits in patients who underwent surgery for apparent early-stage USC, the presence of lymph node metastasis was the main adverse prognostic factors, supporting the prognostic role of the retroperitoneal staging also in this histological subtype.

Identifiants

pubmed: 32808495
pii: 31.e64
doi: 10.3802/jgo.2020.31.e64
pmc: PMC7440990
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e64

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020. Asian Society of Gynecologic Oncology, Korean Society of Gynecologic Oncology.

Déclaration de conflit d'intérêts

No potential conflict of interest relevant to this article was reported.

Références

Int J Gynecol Cancer. 2018 Jul;28(6):1138-1144
pubmed: 29621127
Gynecol Oncol. 2019 Feb;152(2):304-309
pubmed: 30503049
Int J Gynecol Cancer. 2016 Jan;26(1):2-30
pubmed: 26645990
Ann Surg Oncol. 2012 Jan;19(1):259-67
pubmed: 21695563
Gynecol Oncol. 1993 Jan;48(1):32-7
pubmed: 8423019
Gynecol Oncol. 2017 Aug;146(2):234-239
pubmed: 28528918
Brachytherapy. 2019 Jan - Feb;18(1):38-43
pubmed: 30316723
Gynecol Oncol. 2005 Mar;96(3):579-82
pubmed: 15721397
J Natl Cancer Inst. 2008 Dec 3;100(23):1707-16
pubmed: 19033573
Semin Diagn Pathol. 2014 May;31(3):205-15
pubmed: 24951284
Lancet Oncol. 2017 Mar;18(3):384-392
pubmed: 28159465
Int J Gynecol Cancer. 2019 Jan;29(1):60-67
pubmed: 30640685
Gynecol Oncol. 2008 Apr;109(1):11-8
pubmed: 18304622
Am J Obstet Gynecol. 2018 Nov;219(5):463.e1-463.e12
pubmed: 30086293
J Clin Epidemiol. 1994 Nov;47(11):1245-51
pubmed: 7722560
Lancet. 2009 Jan 10;373(9658):125-36
pubmed: 19070889
Gynecol Oncol. 2008 Nov;111(2 Suppl):S44-50
pubmed: 18760450
Gynecol Oncol. 2012 Dec;127(3):651-61
pubmed: 23000148
Obstet Gynecol. 2018 Feb;131(2):304-311
pubmed: 29324598
Lancet Oncol. 2019 Sep;20(9):1273-1285
pubmed: 31345626
Contemp Clin Trials. 2006 Aug;27(4):353-63
pubmed: 16678497
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):208-16
pubmed: 12909235
Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6
pubmed: 18226630
Obstet Gynecol. 2014 Aug;124(2 Pt 1):307-15
pubmed: 25004343
J Clin Oncol. 2009 Nov 10;27(32):5331-6
pubmed: 19805679
Gynecol Oncol. 2005 Dec;99(3):557-63
pubmed: 16154185
Gynecol Oncol. 2004 Dec;95(3):593-6
pubmed: 15581969
Gynecol Oncol. 1994 Sep;54(3):264-8
pubmed: 8088602
Nature. 2013 May 2;497(7447):67-73
pubmed: 23636398

Auteurs

Jvan Casarin (J)

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy. j.casarin@uninsubria.it.

Giorgio Bogani (G)

Department of Gynecologic Oncology, National Cancer Institute, Milan, Italy.

Elisa Piovano (E)

Obstetrics and Gynecology Unit, Regina Montis Regalis Hospital, Mondovì, Italy.

Francesca Falcone (F)

Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy.
Endoscopica Malzoni - Center for Advanced Endoscopic Gynecological Surgery, Avellino, Italy.

Federico Ferrari (F)

Department of Obstetrics and Gynecology, Spedali Civili, Brescia, Italy.

Franco Odicino (F)

Department of Obstetrics and Gynecology, Spedali Civili, Brescia, Italy.

Andrea Puppo (A)

Obstetrics and Gynecology Unit, Regina Montis Regalis Hospital, Mondovì, Italy.

Ferdinando Bonfiglio (F)

Department of Biomedicine, University of Basel, Basel, Switzerland.

Nicoletta Donadello (N)

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Ciro Pinelli (C)

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Antonio Simone Laganà (AS)

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Antonino Ditto (A)

Department of Gynecologic Oncology, National Cancer Institute, Milan, Italy.

Mario Malzoni (M)

Endoscopica Malzoni - Center for Advanced Endoscopic Gynecological Surgery, Avellino, Italy.

Stefano Greggi (S)

Department of Gynecologic Oncology Surgery, Istituto Nazionale Tumori, IRCSS, "Fondazione G. Pascale", Naples, Italy.

Francesco Raspagliesi (F)

Department of Gynecologic Oncology, National Cancer Institute, Milan, Italy.

Fabio Ghezzi (F)

Department of Obstetrics and Gynecology, University of Insubria, Varese, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH